Beyond Air Receives FDA Breakthrough Device Designation for LungFit GO in NTM-PD
核心洞察
The U.S. FDA granted Breakthrough Device Designation to Beyond Air's LungFit GO (搜索) for treating nontuberculous mycobacterial pulmonary disease (搜索) (NTM-PD), a chronic lung condition with limited treatment options.
LungFit GO (搜索) is a portable, ~20 lb. device that generates inhaled nitric oxide from ambient air, enabling patients to self-administer high-dose intermittent therapy at home.
A pilot study published in the Annals of the American Thoracic Society showed high compliance, favorable safety, improved quality-of-life measures, and a trend toward reduced mycobacterial burden, including one case of culture conversion.
Beyond Air, Inc. (搜索) (XAIR) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO (搜索) for the treatment of nontuberculous mycobacterial pulmonary disease (搜索) (NTM-PD). The designation marks a significant milestone for the investigational device, which is designed to deliver high-dose intermittent inhaled nitric oxide (NO) through a portable system, enabling patients to self-administer therapy at home.
NTM-PD is a rare and serious chronic bacterial lung infection associated with substantial morbidity and mortality. The disease is considered an emerging global public health concern, as many infections are difficult to treat and often require prolonged multidrug antibiotic regimens that may continue for up to two years. These complex treatment courses can be difficult to tolerate, are associated with significant adverse events, and can have limited success in difficult-to-treat infections, including Mycobacterium abscessus complex (搜索) (MABSC) and refractory Mycobacterium avium complex (搜索) (MAC). As a result, NTM-PD remains a disease with significant unmet medical need, underscoring the need for novel therapeutic approaches.
Clinical Evidence Supporting the Designation
Results from a pilot study published in the Annals of the American Thoracic Society showed that patients with chronic refractory NTM lung disease were able to safely use the device with high compliance, favorable safety, and signs of improvement in quality-of-life measures. The study also noted a trend toward reduced mycobacterial burden, including one case of culture conversion.
Kenneth Olivier, MD, MPH, of the University of North Carolina - Chapel Hill, noted that the ability to deliver nitric oxide at home represents an important step forward for patients requiring long-term care.
The LungFit GO Platform
LungFit GO (搜索) is an investigational device that has not been cleared or approved for commercial distribution by the FDA or any other regulatory authority. The portable device weighs only approximately 20 lbs. and operates with a standard electrical outlet (120-240 volts). Because NO is generated from ambient air that flows through a reaction chamber, there is an unlimited supply. Beyond Air's proprietary NO2 filters are required for the system to generate and safely deliver NO, as toxic levels of NO2 can result from high concentrations of NO without proper filtration. The filters are equipped with an RFID chip that programs the system with respect to NO concentration, flow rate, and duration of therapy, which the company believes provides maximum flexibility for NO administration.
Beyond Air's CEO Robert Goodman stated that LungFit GO (搜索) has the potential to transform nitric oxide from a hospital-based therapy into a practical home-based treatment platform. He emphasized that the designation validates the unmet need in NTM-PD and enhances the value of the device within the company's nitric oxide platform.
Regulatory and Development Implications
The FDA grants Breakthrough Device Designation when a device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. The program is designed to provide timely access to medical devices to speed up development, assessment, and review for FDA approval.
Beyond Air plans to leverage the enhanced interactions available through the FDA's Breakthrough Devices Program as it finalizes the design of a future clinical study for LungFit GO (搜索) in NTM-PD. The company believes the designation has the potential to streamline the clinical development process and support more efficient advancement of the program toward potential regulatory approval. The Breakthrough Device Designation is expected to facilitate closer FDA interactions and potentially accelerate the path toward larger clinical studies.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air's other LungFit systems, including LungFit GO (搜索), are not approved for commercial use, and the company is not suggesting or promoting NO use over 80 ppm, or use in the home setting, outside of an authorized investigational or clinical study setting.